Type 2 inflammatory skin diseases are driven mainly by T helper 2 lymphocytes (Th2), group 2 innate lymphoid cells (ILC2), and associated cytokines like interleukin (IL)-4, IL-5, and IL-13. Conditions such as atopic dermatitis, bullous pemphigoid, alopecia areata, prurigo nodularis, chronic spontaneous urticaria, hypereosinophilic syndrome, hyperimmunoglobulin E syndrome, alopecia areata, and pruritus, could be related with Type 2 inflammatory. Recent advancements in understanding the mechanisms of Type 2 inflammation have led to the development of numerous novel targeted therapies including monoclonal antibodies against IL-4Rα, IL-5, IL-13, IL-31, JAK inhibitors, and PDE-4 inhibitors significantly expanding the therapeutic landscape and enhancing our comprehension of these diseases. However, the complexity of the disease's pathogenesis still demands thorough investigation to establish standardized treatment protocols.This Research Topic aims to consolidate and expand our current understanding of the pathogenesis and management of Type 2 inflammatory skin diseases. By examining theoretical frameworks and clinical outcomes, this collection seeks to synthesize current knowledge and foster the development of standardized treatment protocols, offering nuanced insights into the underlying mechanisms of these conditions, and potentially steering future therapeutic innovations.To gather further insights into the complexities of Type 2 inflammatory skin diseases, we welcome articles addressing, but not limited to, the following themes:o Mechanistic studies on the roles of specific cells and cytokines in Type 2 inflammationo Evaluation of novel targeted therapies, including their effectiveness and safetyo Results and data from recent clinical trials for new treatmentso Epidemiological findings and their implications for disease understanding and managemento Creation and implementation of clinical guidelines to standardize and improve patient careo Strategies and practices to enhance patient engagement and education in managing their conditionso Comparative analyses on diseases prognosis and outcomesThis topic is open for submissions including original research, reviews, clinical trial analysis, case reports, and more, aiming to engage researchers, clinicians, and patients globally in enhancing the dialogue and knowledge surrounding Type 2 inflammatory diseases.
Type 2 inflammatory skin diseases are driven mainly by T helper 2 lymphocytes (Th2), group 2 innate lymphoid cells (ILC2), and associated cytokines like interleukin (IL)-4, IL-5, and IL-13. Conditions such as atopic dermatitis, bullous pemphigoid, alopecia areata, prurigo nodularis, chronic spontaneous urticaria, hypereosinophilic syndrome, hyperimmunoglobulin E syndrome, alopecia areata, and pruritus, could be related with Type 2 inflammatory. Recent advancements in understanding the mechanisms of Type 2 inflammation have led to the development of numerous novel targeted therapies including monoclonal antibodies against IL-4Rα, IL-5, IL-13, IL-31, JAK inhibitors, and PDE-4 inhibitors significantly expanding the therapeutic landscape and enhancing our comprehension of these diseases. However, the complexity of the disease's pathogenesis still demands thorough investigation to establish standardized treatment protocols.This Research Topic aims to consolidate and expand our current understanding of the pathogenesis and management of Type 2 inflammatory skin diseases. By examining theoretical frameworks and clinical outcomes, this collection seeks to synthesize current knowledge and foster the development of standardized treatment protocols, offering nuanced insights into the underlying mechanisms of these conditions, and potentially steering future therapeutic innovations.To gather further insights into the complexities of Type 2 inflammatory skin diseases, we welcome articles addressing, but not limited to, the following themes:o Mechanistic studies on the roles of specific cells and cytokines in Type 2 inflammationo Evaluation of novel targeted therapies, including their effectiveness and safetyo Results and data from recent clinical trials for new treatmentso Epidemiological findings and their implications for disease understanding and managemento Creation and implementation of clinical guidelines to standardize and improve patient careo Strategies and practices to enhance patient engagement and education in managing their conditionso Comparative analyses on diseases prognosis and outcomesThis topic is open for submissions including original research, reviews, clinical trial analysis, case reports, and more, aiming to engage researchers, clinicians, and patients globally in enhancing the dialogue and knowledge surrounding Type 2 inflammatory diseases.